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Two salts of the anti-HIV drug lamivudine, namely, lamivudine
hydrochloride and lamivudine hydrochloride monohydrate, were
prepared for the first time. Structural relationships and the role of
water in crystal assembly and lamivudine conformation were
established and allowed for a rational approach to understand how
solid state properties could be changed by engineering new salts of
the drug.
The design of new smart crystalline phases of active pharmaceutical
ingredients (API) and the understanding of structural relationships
allow modulation of their solid state features related to the phar-
maceutical performance.1,2 Many drugs have very poor aqueous
solubility and dissolution characteristics in their free base (or free
acid) stable crystal forms, challenging researchers to solve this
undesirable solid state feature. To improve APIs solubility, engi-
neering and screening of salts, cocrystals, solvates, hydrates and
polymorphs are commonly invoked.3,4 In this sense, salt preparation
of crystalline solids is one of the most attractive alternatives because
of higher functional and technical characteristics of salts, such as
solubility, stability and manufacturability, beyond low costs and
practical procedures of preparation, high yield, reproducibility and
purity.5,6Furthermore, the engineering, prediction and understanding
of salt formation are based on elegant chemical approaches on
assembly mechanisms driven by molecular recognition events, which
contribute to an easier legal process for protection of intellectual
property on novel API crystal phases due to nonobviousness of
designed molecular salts.7
Lamivudine (b-L-20,30-dideoxy-30-thiacytidine, 3TC) belongs to the
class of nucleoside reverse transcriptase inhibitors (NRTIs), and it is
being used worldwide in anti-HIV therapy8 and also against hepatitis
B virus.9 Lamivudine can be described as a cytidine analog having
a sulfur atom at 30-position instead of methylene group as occurs in
the canonical nucleoside. Concerning its asymmetry centers, the two
chiral C10 and C40 carbons are present with S and R absolute
configurations, respectively. Due to this chirality, lamivudine always
crystallizes in non-centrosymmetric space groups. Recent studies
have demonstrated the ability of lamivudine to crystallize together
with several small molecules in multicomponent molecular co-crys-
tals,10–13 even though simple salts of the drug with inorganic coun-
terions have not been reported.
Indeed, APIs containing protonable imine groups such as lam-
ivudine can form salts with simple inorganic acids such as hydro-
chloric acid. Here, we reported the preparation‡ and the crystal
structuresx of two lamivudine salts, namely, lamivudine hydrochlo-
ride (1) and lamivudine hydrochloride monohydrate (2).
Lamivudine stoichiometrically crystallized together with
hydrochloric acid in two salt forms depending on the solvent
system. An anhydrate phase and a monohydrate form of lam-
ivudine hydrochloride were synthesized after solvent combina-
tions and hydrochloric acid concentrations in water solutions
were screened. From the three-component system of lamivudine,
0.28 mol L1 solution of hydrochloric acid in water and iso-
propanol, crystals of 1 were obtained, while crystals of 2 were
isolated from the two-component system of lamivudine and the
same water solution of hydrochloric acid. According to the
hydrochloric acid concentrations used in both crystallization
media, the pH values of the two solvent systems were below 2.
Under such acidic conditions, the conjugated acid form of lam-
ivudine (pKa 4.30)
14 prevailed over the neutral one. Before the
solvent system began to evaporate, the concentration of the
protonated form already was at least 200-fold higher than that of
the base. By using both crystallization systems described above,
it was expected therefore that lamivudine would assemble into
solid state phases only made up of positively charged drug
molecules, as it was observed in the structures of 1 and 2.
Both lamivudine salts crystallize in the P21 space group with one
(lamivudine)+ cation and one chloride anion in the asymmetric units
(Fig. 1). One water molecule also composes the asymmetric unit of
the salt hydrate. In 1 and 2, the drug backbones resemble one another
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and both exhibit a conformation commonly found in canonical
nucleotides of DNA (Fig. 2). Cytosine and oxathiolane rings are
present with an anti conformation (C2–N1–C10–O10 torsion
measures 161.9(2)15 and 164.2(3) in 1 and 2) and C30-endo pucker
(C20–C10–O10–C40 torsion measures 7.1(3) and 10.2(4) in 1
and 2), respectively.
However, there is a great conformational difference between the
drug backbones. In the salt anhydrate, the hydroxyl group bonded to
the methylene sp3-hybridized 50-carbon adopts an equatorial position
on the same side of the sulfur atom of the five-membered oxathiolane
ring. In contrast, the 50-hydroxyl group is axially bonded to carbon
on the same side of cytosine in 2, in an equivalent position of one of
the two 50-methylene hydrogens of 1 (Fig. 2). These conformations
observed in lamivudine molecules of the hydrochloride salts are
related to a rotation of about 120 on the C40–C50 bond axis. It is
important to highlight that the CH2OH group conformations are
related to the hydrogen bonding patterns assembling the hydro-
chloride salt structures (see in sequence). The O10–C40–C50–O50 and
S30–C40–C50–O50 dihedral angles measure175.8(2) and 65.1(3) in
1 and 63.4(4) and57.4(4) in 2. One can observe that there are gaps
of 239.2 and 122.5 in the values of the O10–C40–C50–O50 and S30–
C40–C50–O50 torsions between the hydrochloride salts of lamivudine,
which is in agreement with the 3-fold rotation on the C40–C50
bond axis.
Supramolecular architectures of 1 and 2 were layered with lam-
ivudinemolecules base-stacked along the [100] direction throughp–p
interactions, with interlayer spaces measuring 3.28(4) A and
3.30(1) A, respectively. Furthermore, each chloride anion is a double
hydrogen bonding acceptor from lamivudine in both structures.
Through their imine and amine groups, protonated cytosine rings of
the drug donate hydrogen bonds to chloride in a bifurcated pattern
(Fig. 3). In 1, the other NH2 hydrogen that is not involved in the
bifurcated hydrogen bonds also interacts with a 21-screw axis
symmetry related chloride anion, which assembles one-dimensional
chains parallel to the [010] direction made up of alternate cations and
anions. Along this direction, lamivudine units related by the 21-screw
axis symmetry are connected through a classical hydrogen bonding
between the 50-hydroxyl and 2-carbonyl groups. This O–H/O
contact can be viewed as a cross-linker between the [010]-packed
chains of 1 along the [101] direction, giving rise to hydrogen bonded
2D layers (Fig. 3). In 2, the other NH2 hydrogen is hydrogen bonded
to water that lies in the position of a 21-screw axis symmetry related
chloride which would be connected to the amine hydrogen in 1. In
this way, in the salt hydrate water plays the hydrogen bonding
acceptor role of a chloride in 1. Furthermore, each water molecule is
a double hydrogen bonding donor to chloride anions. This hydrogen
bonding pattern gives rise to wires of alternate chloride and water
fragments along the [100] direction inwhich lamivudinemolecules are
anchored by means of hydrogen bonding donation through their
cytosine fragments (Fig. 3). In addition, the hydrogen bonding
between the 50-hydroxyl and 2-carbonyl groups also occurs in 2,
although lamivudine molecules hydrogen bonded through this
contact are related by the translation symmetry in this structure. The
wiresmade up of water and chloride anions with attached lamivudine
cations are 21-screw axis symmetry related in 2. These supramolecular
wires are packed along the b axis only through vdW interactions.
By inspecting both structures of 1 and 2, conformational differ-
ences and crystal assembly changes can be understood as conse-
quences of water inclusion (Fig. 4). Water is a hydrogen bonding
acceptor from lamivudine and also acts as a ‘‘molecular hook’’16 to
connect translation symmetry related (lamivudine)+(Cl) pairs along
the [101] direction in 2. The ‘‘water hook’’ donates one of the two
hydrogens to a chloride of an adjacent (lamivudine)+(Cl) pair
arranged parallel to this crystallographic direction. This interaction
between water and chloride is related to the conformational differ-
ence aforementioned. The presence of watermolecules in the lattice as
hydrogen bonding donors to chloride anions becomes close together
translation symmetry related lamivudine molecules so that the O–
H/Ohydrogen bonding between them is formed. Relative to the salt
anhydrate, a 3-fold rotation on the C40–C50 bond axis occurs in the
salt hydrate to position the 50-hydroxyl group of one lamivudine
molecule toward the carbonyl moiety of another one (Fig. 4).
In an attempt to predict solid state properties related to the
pharmaceutical performance of these new lamivudine salts, rela-
tionships between structural features and crystal packing efficiency
were established. As it was before described, classical hydrogen bonds
between lamivudine molecules and chloride counterions and between
lamivudine molecules are responsible for the assembly of strongly
bonded 2D layers that are stacked on top of each other to form
a closely packed 3D network in 1, while only weak contacts pack
lamivudine-anchored chloride-water wires along the [010] direction of
2. Consequently, we can conclude that the crystal packing of 1 is
more efficient than that of 2, which is corroborated by the fact that
the calculated density of 1 (1.599 g cm3) is higher than that of 2
(1.524 g cm3). This approach can be useful to rationalize solid state
behaviors of the salts, as, for instance, equilibrium solubility and
kinetic dissolution.
Fig. 1 Asymmetric units of lamivudine hydrochloride (1) and lam-
ivudine hydrochloride monohydrate (2). Hydrogens are outlined as
arbitrary radius spheres, and the ellipsoids are at the 50% probability
level.
Fig. 2 Superposition of lamivudine conformers assembling the struc-
tures of 1 and 2. The hydrogen atoms were hidden for clarity. Oxathio-
lane rings are highlighted in order to detach the 3-fold rotation on the
C40–C50 bond axis.
2374 | CrystEngComm, 2012, 14, 2373–2376 This journal is ª The Royal Society of Chemistry 2012
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Fig. 3 Assembling the structures of (a) 1 and (b) 2. Black and gray arrows indicate the crystallographic directions parallel and normal to the projection
planes, respectively.
Fig. 4 Effect of the water inclusion in the crystal lattice of 2. (a) Two translation symmetry related (lamivudine)+Cl pairs are packed along the [010]
and [101] directions in 1 and 2, respectively. (b) In 2, water lies in the corresponding site of a 21-screw axis symmetry related chloride anion of 1. (c) The
hydrogen bonding between water and a translation symmetry related chloride anion (red arrow) is responsible for the displacement of a neighboring
(lamivudine)+Cl pair (black arrow) and then driving the rotation on the C40–C50 bond axis to form the hydrogen bonding between the 50-hydroxyl
and 2-carbonyl groups (circled) of translation symmetry related molecules. (d) In 1, the hydrogen bonding between the 50-hydroxyl and 2-carbonyl
groups occurs between 21-screw axis symmetry related lamivudine fragments. Equivalent positions: (i) 1 + x, y, 1 + z; (ii)x, 0.5 + y, 1  z; (iii) 1  x,
0.5 + y, z.
This journal is ª The Royal Society of Chemistry 2012 CrystEngComm, 2012, 14, 2373–2376 | 2375
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In summary, anhydrate and monohydrate versions of lamivudine
hydrochloride were prepared and their structures were elucidated and
understood on the basis of crystal assembly inspections and confor-
mational analyses. Such structural knowledge will be of valuable use
for the comprehension of related solid state features. Because most
hydrochloride salts are more soluble than the parent APIs, these new
lamivudine salts reported here are expected to be improved from
a pharmaceutical point of view,meaning an important advance in the
solid state chemistry of lamivudine.
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Notes and references
‡ Preparation. Lamivudine form II was used as the starting material for
preparation of 1 and 2. The authenticity and purity of lamivudine form II
were first confirmed by single crystal and powder X-ray diffraction
techniques before using it to prepare the crystalline modifications. For
preparation of 1, a quantity of the drug (10 mg, 0.04 mmol) was dissolved
in isopropanol (5 ml, 66 mmol) under stirring (5 min) on a water bath
(308 K). The solution was then allowed to cool to room temperature. By
adding a 0.28 mol L1 solution of hydrochloric acid in water (0.25 ml,
0.07 mmol) to the preparation of the drug in isopropyl alcohol, crystals of
1 could be obtained after stirring (5 min, 298 K) and slow evaporation of
the resulting solution upon standing (7 days, 298 K). On the other hand,
by dissolution of lamivudine (10 mg, 0.04 mmol) in double-distilled water
(5 ml, 0.28 mol) under shaking (10 min) on a water bath (313 K), crystals
of 2 were obtained after addition of the same hydrochloric acid solution
(0.25 ml, 0.07 mmol) to the aqueous solution of lamivudine, cooling to
room temperature, stirring of the mixture (5 min, 298 K) and standing for
8 days at room temperature.
x Structure determination. Well-grown single crystals of 1 and 2
measuring 0.43  0.10  0.05 mm3 and 0.58  0.10  0.03 mm3,
respectively, were isolated from the glass crystallizers after the crystalli-
zation period. They were mounted on a k-goniostat and exposed to
graphite-monochromated X-ray beam (Mo Ka, l ¼ 0.71073 A) using an
Enraf-Nonius Kappa-CCD diffractometer equipped with a CCD camera
of 95 mm. The data collection strategy was calculated by setting 4 scans
and u scans with k offsets. The crystallographic software used was as
follows: COLLECT17 (X-ray diffraction experiment monitoring), HKL
Denzo–Scalepack18 package of software (indexing, integration and
scaling of raw data), SHELXS-97 (ref. 19) (structure solving), SHELXL-
97 (ref. 19) (structure refinement), MERCURY20 and ORTEP-3 (ref. 21)
(structure analysis and graphical representations). The structures were
solved using the direct methods of phase retrieval, in which all non-
hydrogen atoms of an asymmetric unit were located from the electronic
density Fourier map. The solved model was refined by the full-matrix
least squares method based on F2. In the refinements, free anisotropic and
fixed isotropic thermal displacement parameters were set for non-
hydrogen and hydrogen atoms, respectively. The isotropic thermal
displacement parameters of the C–H andN–H hydrogen atoms were 20%
greater than the equivalent isotropic parameter of the corresponding
atom. For the O–H hydrogen atoms, this percentage was set to 50%.
Concerning the positions of hydrogens, C–H bond distances were ster-
eochemically defined according to the riding model. Therefore, (x, y, z)
fractional coordinates of these hydrogen atoms were constrained in the
refinements. The coordinates of O–H, N–H and N+–H hydrogen atoms
were primarily defined as those of the electronic density peaks located
from the difference Fourier map. After these positions were taken, they
were refined freely.
Crystal data for 1. (C8H12N3O3S)Cl, Mw ¼ 265.72, monoclinic, a ¼
5.7060(2) A, b ¼ 11.9670(5) A, c ¼ 8.3401(4) A, b ¼ 104.273(2), V ¼
551.91(4) A3, T¼ 298(2) K, space group P21, Z¼ 2,Dc ¼ 1.599 g cm3, m
(MoKa) ¼ 0.531 mm1, GAUSSIAN absorption correction (Tmin ¼
0.866, Tmax ¼ 0.974), q-range for data collection¼ 3.04–26.63, 6# h#
7, 14 # k # 15, 10 # l # 10, 6374 reflections collected, 2284 unique
(Rint ¼ 0.0646), completeness to q ¼ 26.63 of 99.0%, F000 ¼ 276, 157
parameters refined, S ¼ 1.030, R1(I > 2s(I)) ¼ 0.0365, wR2(I > 2s(I)) ¼
0.0896, R1(all data) ¼ 0.0438, wR2(all data) ¼ 0.0943, largest diff. peak/
hole ¼ 0.293/0.234 e A3, Flack parameter ¼ 0.09(7) (1080 Friedel
pairs), CCDC-751365 (for low temperature structure, CCDC-751367).
Crystal data for 2. (C8H12N3O3S)(H2O)Cl,Mw¼ 283.73, monoclinic, a¼
5.2927(2)A, b¼ 17.252(1)A, c¼ 6.8518(4)A, b¼ 98.865(3),V¼ 618.18
(6) A3, T ¼ 298(1) K, space group P21, Z ¼ 2, Dc ¼ 1.524 g cm3, m
(MoKa) ¼ 0.485 mm1, GAUSSIAN absorption correction (Tmin ¼
0.881, Tmax ¼ 0.986), q-range for data collection¼ 3.83–25.10, 6# h#
5, 19 # k # 19, 7 # l # 7, 7849 reflections collected, 1854 unique
(Rint ¼ 0.0840), completeness to q ¼ 25.10 of 98.9%, F000 ¼ 296, 172
parameters refined, S ¼ 1.039, R1(I > 2s(I)) ¼ 0.0364, wR2(I > 2s(I)) ¼
0.0754, R1(all data) ¼ 0.0528, wR2(all data) ¼ 0.0823, largest diff. peak/
hole ¼ 0.164/0.212 e A3, Flack parameter ¼ 0.06(8) (889 Friedel
pairs), CCDC-751366 (for low temperature structure, CCDC-751368).
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